Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study

Ali, Mohammad Daud; Almadan, Leena Zakariya; Alghamdi, Ruba Ahmed; Alghamdi, Alanood Saleh; Almarhoon, Sarah Ali; Hassan, Yousif A. M.; Ahmad, Ayaz; Ghosn, Sherihan Ahmad; Banu, Nuzhat; Eltrafi, Zainab

doi:10.2147/idr.s374265

Cited by 8 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study showed that the most frequent adverse effects were pain at the injection site, fatigue, muscle pain, swelling at the injection site, headache, fever and chills. These findings are in accordance with the literature regarding the adverse effects of the first booster dose [14–18,22,23]. Moreover, a recent systematic review investigated the prevalence of adverse effects after the primary COVID-19 vaccine doses and found that the most frequent adverse effects among 10,632 participants were pain at the injection site (77.3%), muscle pain (39.7%), swelling at the injection site (34%), headache (33.3%), chills (18.3%), fever (18%), swollen lymph nodes (8%), nausea (7.9%), and shortness of breath (7.6%) [11].…”

Section: Discussionsupporting

confidence: 93%

“…Literature supports this finding since two other studies found that all participants had adverse effects after the first booster dose [20,21]. Other studies found also high prevalence of adverse effect after the first booster dose ranging from 74.7% to 89% [14][15][16][17]22,23]. Slight differences in prevalence of adverse effects among studies could be attributed to different study designs, populations, and definitions.…”

Section: (Which Was Not Certified By Peer Review)mentioning

confidence: 79%

See 1 more Smart Citation

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Galanis

Katsiroumpa

Vraka

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: In general, COVID-19 vaccines are safe and effective, but minor adverse effects are common. Objective: To estimate the prevalence of adverse effects after the first COVID-19 booster dose, and to identify possible risk factors. Material and methods: We conducted a cross-sectional study with a convenience sample in Greece during November 2022. We measured several adverse effects after the booster dose, such as pain at the injection site, swelling at the injection site, fatigue, muscle pain, headaches, fever, chills, nausea, etc. We considered gender, age, chronic disease, self-assessment of health status, COVID-19 diagnosis, and self-assessment of COVID-19 course as possible predictors of adverse effects. Results: In our sample, 96% developed at least one adverse effect. Half of the participants (50.2%) developed one to five adverse effects, 35.9% developed six to ten adverse effects, and 9.5% developed 11 to 16 adverse effects. Mean number of adverse effects was 5.5. The most frequent adverse effects were pain at the injection site (84.3%), fatigue (70.8%), muscle pain (61%), swelling at the injection site (55.2%), headache (49.8%), fever (42.9%), and chills (41%). Females developed more adverse effects than males (p<0.001). Also, we found a positive relationship between severity of COVID-19 symptoms and adverse effects of COVID-19 vaccines (p=0.005). Moreover, younger age was associated with increased adverse effects (p<0.001). Conclusions: Almost all participants in our study developed minor adverse effects after the booster dose. Female gender, worse clinical course of COVID-19, and decreased age were associated with increased adverse effects.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: (Which Was Not Certified By Peer Review)mentioning

confidence: 79%

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Galanis

Katsiroumpa

Vraka

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In fact, describing the side effects of booster vaccines could help to confirm the safety of these vaccines and, therefore, help to reduce the phenomenon of vaccine (booster) hesitancy, which is a phenomenon described for both primer and booster doses of COVID-19 in Algeria [26,29] and around the world [30,31]. Only limited data are available around the world about the side effects of boosters [16,20,[32][33][34][35][36]. Moreover, little is known about the frequency of these side effects in Algeria.…”

Section: Discussionmentioning

confidence: 99%

Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population

et al. 2022

View full text Add to dashboard Cite

COVID-19 booster vaccines have been adopted in almost all countries to enhance the immune response and combat the emergence of new variants. Algeria adopted this strategy in November 2021. This study was conducted to consider the self-reported side effects of COVID-19 booster vaccines by Algerians who were vaccinated with a booster dose of one of the approved inactivated-virus vaccines, such as BBIBP-CorV and CoronaVac, or one of the adenoviral-vector-based vaccines, such as Gam-COVID-Vac, AZD1222 and Ad26.COV2.S, and to determine the eventual risk factors. A cross-sectional study using an online self-administered questionnaire (SAQ) was conducted in Algeria between 28 April 2022, and 20 July 2022. A descriptive analysis of the 196 individuals who were included showed a nearly equal distribution of adenoviral- (52%) and inactivated-virus vaccines (48%) and of males (49.5%) and females (50.5%). The results showed that 74.7% of the studied population reported at least one local or systemic side effect. These side effects were more frequent among adenoviral-vector vaccinees (87.3%) than inactivated-virus vaccinees (60.6%) (sig. < 0.001). Injection site pain (40.3%), heat at the injection site (21.4%), and arm pain (16.3%) were the most common local side effects. These signs generally appeared in the first 12 h (73.3%) and generally lasted less than 24 h (32.8%). More interestingly, these signs differed from those that followed the administration of primer doses (48.5%) and were generally more severe (37%). The same observation was reported for systemic side effects, where the signs were especially most severe in the adenoviral-vaccinated group (49.4% vs. 20.8%; sig. = 0.001). These signs generally appeared within the first day (63.6%) and mostly disappeared before two days (50.8%), with fatigue (41.8%), fever (41.3%), and headache (30.1%) being the most common. Adenoviral-vector vaccinees (62.7%) were more likely to use medications to manage these side effects than were inactivated-virus vaccinees (45.7%) (sig. = 0.035) and paracetamol (48.5%) was the most-used medication. Adenoviral-based vaccines were the types of vaccines that were most likely to cause side effects. In addition, being female increased the risk of developing side effects; regular medication was associated with local side effects among inactivated-virus vaccinees; and previous infection with COVID-19 was associated with systemic and local side effects among adenovirus-based vaccinees. These results support the short-term safety of booster vaccines, as has been reported for primer doses.

show abstract

“…Another study conducted in Slovakia among health workers did not differ much from what was mentioned in previous studies, where the side effects of the vaccine were injection site pain (85.2%), fatigue (54.2%), headache (34.3%), muscle pain (28.4%), and chills (26.4%) [16]. Several studies around the world nd that muscle pain in injection sites is the most prevalent side effect symptom of vaccines [17][18][19][20][21][22]. The study conducted by Zare in Iran [23] revealed that Pain and tenderness at the injection site, fever, and muscle pain are the most common side effect and this coincides with all the studies around the world that have been conducted so far among healthcare staff, which con rmed that the vaccine is safe and has no serious side effects.…”

Section: Discussionmentioning

confidence: 96%

Physical side effects of covid-19 vaccines reported among healthcare workers in Sudan: A cross-sectional study

Elmadani

Altijani

Tamomh

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: COVID-19 is quickly becoming a global health issue. For the first time in the history of extremely contagious illnesses, a vaccine has been created in one year. Vaccination is having a beneficial impact across the globe. Elimination of this sickness is still far from the reality due to virus mutations. Methods: A descriptive, cross-sectional study was conducted to investigate the side effects of the COVID-19 vaccine among healthcare workers in Kosti Teaching Hospital, Sudan (October 2021- June 2022). Google forms were used to collect data. Samples were taken using total coverage. The data were analyzed using SPSS v28 and the association between variables was checked using the Q-square and Fisher's Exact Test. Result: This study includes (133) participants, the majority are female (77.4%) and the rest were male (22.6%) and the main age group is (37.98 ± 9.5 SD) years. About three-quarters of the study population )76.7%) showed side effects after getting a vaccine. The following adverse effects were experienced by study participants: mild pain at the injection site (77.5%), fever (65%), headache (50%) and fatigue (43%). About 7% were unable to work the next day owing to side effects. Significant differences were observed between the side effects and marital status; p-value = (.005), type of vaccine p-value = (.042) and age p-value = (.021). No significant differences between vaccine side effects and age, previous infection with COVID-19, gender, occupation, number of hours spent at work and infection with other chronic illnesses (p-value< 0.05). Conclusion: Based on current research, pain at the injection site is the most frequent adverse reaction, demonstrating the vaccine's safety and the absence of any problems or lethal effects. Additionally, these side effects don't significantly affect daily activities.

show abstract

Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study

Cited by 8 publications

References 33 publications

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece

Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population

Physical side effects of covid-19 vaccines reported among healthcare workers in Sudan: A cross-sectional study

Contact Info

Product

Resources

About